Cargando…

Frequency and timing of antivascular endothelial growth factor treatment for eyes with centre-involved diabetic macular oedema and good vision: Protocol V results in context

Detalles Bibliográficos
Autores principales:	Do, Diana V, Moini, Hadi, Wykoff, Charles C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9345046/ https://www.ncbi.nlm.nih.gov/pubmed/36161828 http://dx.doi.org/10.1136/bmjophth-2022-000983

Ejemplares similares

Antivascular Endothelial Growth Factor Dosing Frequency and Visual Outcomes in Macular Edema Following Central Retinal Vein Occlusion
por: Modi, Yasha S., et al.
Publicado: (2021)

Antivascular endothelial growth factor for macular oedema secondary to retinal vein occlusion: a systematic review and meta-analysis
por: Xu, Shanshan, et al.
Publicado: (2022)

Comparing vision and macular thickness in neovascular age-related macular degeneration, diabetic macular oedema and retinal vein occlusion patients treated with intravitreal antivascular endothelial growth factor injections in clinical practice
por: Gurung, Rajya L, et al.
Publicado: (2021)

Anti-vascular endothelial growth factor dosing frequency and visual outcomes in macular oedema following branch retinal vein occlusion
por: Modi, Yasha S., et al.
Publicado: (2023)

Use of antivascular endothelial growth factor for diabetic macular edema
por: Karim, Rushmia, et al.
Publicado: (2010)

Burden of diabetic macular oedema in patients receiving antivascular endothelial growth factor therapy in South Korea: a healthcare resource use and cost analysis
por: Jeon, Ha-Lim, et al.
Publicado: (2020)

Antivascular Endothelial Growth Factor Agents for Neovascular Age-Related Macular Degeneration
por: Zampros, Ilias, et al.
Publicado: (2012)

Resistance to antivascular endothelial growth factor treatment in age-related macular degeneration
por: Tranos, Paris, et al.
Publicado: (2013)

Healthcare resource use and costs of diabetic macular oedema for patients with antivascular endothelial growth factor versus a dexamethasone intravitreal implant in Korea: a population-based study
por: Cho, HyunJeong, et al.
Publicado: (2019)

Combined argon laser photocoagulation and antivascular endothelial growth factor for management of macular polypoidal choroidal vasculopathy
por: Sen, Parveen, et al.
Publicado: (2016)

Ten-year outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration
por: Chandra, Shruti, et al.
Publicado: (2020)

Incidence of Acute Endophthalmitis after Intravitreal Antivascular Endothelial Growth Factor Injection in Age-related Macular Degeneration
por: Seong, Hyo Jin, et al.
Publicado: (2022)

Commentary: Antivascular endothelial growth factor and retinopathy of prematurity
por: Dudani, Ajay Indur, et al.
Publicado: (2019)

Changes in Macular Microvascular Structure in Macular Edema Secondary to Branch Retinal Vein Occlusion Treated with Antivascular Endothelial Growth Factor for One Year
por: Song, Shuang, et al.
Publicado: (2021)

ASSOCIATION BETWEEN ANATOMICAL AND CLINICAL OUTCOMES OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR
por: Nguyen, Vuong, et al.
Publicado: (2021)

Choroidal Vascularity Index as a Biomarker for Visual Response to Antivascular Endothelial Growth Factor Treatment in Diabetic Macular Edema
por: Dou, Ningxin, et al.
Publicado: (2021)

Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: A post hoc analysis of Protocol I data
por: Sadda, Srinivas R., et al.
Publicado: (2019)

Should we still be performing macular laser for non-centre involving diabetic macular oedema? Results from a UK centre
por: Scanlon, Peter H., et al.
Publicado: (2021)

Clinically meaningful visual improvements and predictors of early vision gains with ranibizumab for diabetic macular oedema
por: Morse, Lawrence, et al.
Publicado: (2019)

Predictive factors of better outcomes by monotherapy of an antivascular endothelial growth factor drug, ranibizumab, for diabetic macular edema in clinical practice
por: Sato, Shinri, et al.
Publicado: (2017)

Change in choroidal volume after dexamethasone intravitreal implant in eyes with diabetic macular oedema
por: Posch‐Pertl, Laura, et al.
Publicado: (2018)

Acuity and colour vision changes post intravitreal dexamethasone implant injection in patients with diabetic macular oedema
por: Abdel-Hay, Ahmed, et al.
Publicado: (2018)

Long-Term Visual Outcomes for a Treat-and-Extend Antivascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration: Up to Seven-Year Follow-Up
por: Javidi, Simon, et al.
Publicado: (2020)

Better visual outcome at 1 year with antivascular endothelial growth factor treatment according to treat‐and‐extend compared with pro re nata in eyes with neovascular age‐related macular degeneration
por: Aurell, Sandra, et al.
Publicado: (2018)

Association between Inflammatory Factors in the Aqueous Humor and Hyperreflective Foci in Patients with Intractable Macular Edema Treated with Antivascular Endothelial Growth Factor
por: Li, Min, et al.
Publicado: (2021)

Full-thickness macular hole formation following antivascular endothelial growth factor injection in a case of hemicentral retinal vein occlusion
por: Mitra, Srijita, et al.
Publicado: (2021)

A longitudinal study to assess the frequency and cost of antivascular endothelial therapy, and inequalities in access, in England between 2005 and 2015
por: Hollingworth, William, et al.
Publicado: (2017)

Impact of metabolic control on macular thickness in diabetic macular oedema
por: Peng, Yi-Jie, et al.
Publicado: (2017)

Retrospective Analysis of Treatment Patterns in Pseudophakic Diabetic Macular Oedema Eyes Treated with Anti-VEGF
por: Zou, Di, et al.
Publicado: (2021)

Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11
por: Wildiers, H, et al.
Publicado: (2003)

Antiangiogenic drugs in the management of ocular diseases: Focus on antivascular endothelial growth factor
por: Sassa, Yukio, et al.
Publicado: (2010)

The Use of Antivascular Endothelial Growth Factor Agents in the Perioperative Period in Diabetic Vitrectomy
por: Abu-Yaghi, Nakhleh E., et al.
Publicado: (2012)

Promising Novel Treatment against Keloids: Antivascular Endothelial Growth Factor Agents
por: Abtahi-Naeini, Bahareh, et al.
Publicado: (2019)

Maculopapular rash after intravitreal injection of an antivascular endothelial growth factor, aflibercept, for treating age-related macular degeneration: A case report
por: Nagai, Norihiro, et al.
Publicado: (2017)

Predictors of vision‐related quality of life in patients with macular oedema receiving intra‐vitreal anti‐VEGF treatment
por: Rausch‐Koster, Petra T., et al.
Publicado: (2022)

Optical coherence tomography imaging of macular oedema
por: Trichonas, George, et al.
Publicado: (2014)

Remote examination of exudates-impact of macular oedema
por: Punniyamoorthy, Uma, et al.
Publicado: (2018)

Indicators of Visual Prognosis in Diabetic Macular Oedema
por: Sen, Sagnik, et al.
Publicado: (2021)

Diabetic Macular Oedema Guidelines: An Australian Perspective
por: Yuen, Yew Sen, et al.
Publicado: (2023)

Impact of image averaging on vessel detection using optical coherence tomography angiography in eyes with macular oedema and in healthy eyes
por: Le Boité, Hugo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qvkjn06l6ug2rrvpfqcvh5otnj